XML 19 R4.htm IDEA: XBRL DOCUMENT v3.25.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Revenues:    
Clinical treatment programs – US $ 170 $ 202
Total Revenues 170 202
Costs and Expenses:    
Production costs 31 42
Research and development 6,197 10,939
General and administrative 13,714 21,137
Total Costs and Expenses 19,942 32,118
Operating loss (19,772) (31,916)
(Loss) gain on investments (93) 200
Interest and other income 5,192 1,069
Interest expense (585)
Gain on sale of fixed assets 18
(Loss) on warrant issuance (458)
(Loss) gain from sale of income tax operating losses (1,604) 1,667
Net Loss $ (17,320) $ (28,962)
Basic loss per share $ (0.31) $ (0.60)
Diluted loss per share $ (0.31) $ (0.60)
Weighted average shares outstanding basic 56,016,870 48,585,404
Weighted average shares outstanding diluted 56,016,870 48,585,404